TABLE OF CONTENTS
Volume 19, Issue 10 (October 2005)
Leading Article
Proteomic analysis of childhood leukemia
C M Hegedus, L Gunn, C F Skibola, L Zhang, R Shiao, S Fu, E A Dalmasso, C Metayer, G V Dahl, P A Buffler and M T Smith
Leukemia 19: 1713-1718; advance online publication, September 1, 2005; doi:10.1038/sj.leu.2403897
Reviews
Gatekeeper pathways and cellular background in the pathogenesis and therapy of AML
J Cammenga
Leukemia 19: 1719-1728; advance online publication, August 18, 2005; doi:10.1038/sj.leu.2403894
Novel targeted drugs for the treatment of multiple myeloma: from bench to bedside
B Bruno, L Giaccone, M Rotta, K Anderson and M Boccadoro on behalf of the Multiple Myeloma Research Foundation
Leukemia 19: 1729-1738; advance online publication, August 11, 2005; doi:10.1038/sj.leu.2403905
Myeloproliferative disorders: the centrosome connection
B Delaval, H Lelièvre and D Birnbaum
Leukemia 19: 1739-1744; advance online publication, August 18, 2005; doi:10.1038/sj.leu.2403926
Original Manuscripts
Infectious Medicine
Common genetic variants in the interleukin-6 and chitotriosidase genes are associated with the risk for serious infection in children undergoing therapy for acute myeloid leukemia
T Lehrnbecher, T Bernig, M Hanisch, U Koehl, M Behl, D Reinhardt, U Creutzig, T Klingebiel, S J Chanock and D Schwabe
Leukemia 19: 1745-1750; advance online publication, August 18, 2005; doi:10.1038/sj.leu.2403922
Acute Non Lymphocytic Leukemia
Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors
C A Bradbury, F L Khanim, R Hayden, C M Bunce, D A White, M T Drayson, C Craddock and B M Turner
Leukemia 19: 1751-1759; advance online publication, August 25, 2005; doi:10.1038/sj.leu.2403910
Cell line OCI/AML3 bears exon-12 NPM gene mutation-A and cytoplasmic expression of nucleophosmin
H Quentmeier, M P Martelli, W G Dirks, N Bolli, A Liso, R A F MacLeod, I Nicoletti, R Mannucci, A Pucciarini, B Bigerna, M F Martelli, C Mecucci, H G Drexler and B Falini
Leukemia 19: 1760-1767; advance online publication, August 4, 2005; doi:10.1038/sj.leu.2403899
Gemtuzumab ozogamicin (Mylotarg®) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell'Adulto Leukemia Groups
S Amadori, S Suciu, R Stasi, R Willemze, F Mandelli, D Selleslag, C Denzlinger, P Muus, R Stauder, Z Berneman, J Pruijt, F Nobile, V Cassibba, J-P Marie, F Beeldens, L Baila, M Vignetti and T de Witte
Leukemia 19: 1768-1773; advance online publication, August 4, 2005; doi:10.1038/sj.leu.2403901
Chronic Myeloid Leukemia, BCR QBL Studies QND Myeloproliferative Disorders
Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development
A Burchert, Y Wang, D Cai, N von Bubnoff, P Paschka, S Müller-Brüsselbach, O G Ottmann, J Duyster, A Hochhaus and A Neubauer
Leukemia 19: 1774-1782; advance online publication, September 1, 2005; doi:10.1038/sj.leu.2403898
Acute Lymphoblastic Leukemia
CDK2 catalytic activity and loss of nuclear tethering of retinoblastoma protein in childhood acute lymphoblastic leukemia
N M R Schmitz, K Leibundgut and A Hirt
Leukemia 19: 1783-1787; advance online publication, August 18, 2005; doi:10.1038/sj.leu.2403900
CLL and Normal B and T Cells
Increased expression of CD152 (CTLA-4) by normal T lymphocytes in untreated patients with B-cell chronic lymphocytic leukemia
M Motta, L Rassenti, B J Shelvin, S Lerner, T J Kipps, M J Keating and W G Wierda
Leukemia 19: 1788-1793; advance online publication, August 11, 2005; doi:10.1038/sj.leu.2403907
Stem Cells
Direct evidence for cooperating genetic events in the leukemic transformation of normal human hematopoietic cells
J K Warner, J C Y Wang, K Takenaka, S Doulatov, J L McKenzie, L Harrington and J E Dick
Leukemia 19: 1794-1805; advance online publication, August 11, 2005; doi:10.1038/sj.leu.2403917
Differentiation
Retinoid/arsenic combination therapy of promyelocytic leukemia: induction of telomerase-dependent cell death
I Tarkanyi, C Dudognon, J Hillion, F Pendino, M Lanotte, J Aradi and E Ségal-Bendirdjian
Leukemia 19: 1806-1811; advance online publication, August 18, 2005; doi:10.1038/sj.leu.2403923
Translational study of vitamin D differentiation therapy of myeloid leukemia: effects of the combination with a p38 MAPK inhibitor and an antioxidant
Q Wang, J S Harrison, M Uskokovic, A Kutner and G P Studzinski
Leukemia 19: 1812-1817; advance online publication, August 18, 2005; doi:10.1038/sj.leu.2403916
Lymphoma
Cytogenetic analysis delineates a spectrum of chromosomal changes that can distinguish non-MALT marginal zone B-cell lymphomas among mature B-cell entities: a description of 103 cases
E Callet-Bauchu, L Baseggio, P Felman, A Traverse-Glehen, F Berger, D Morel, S Gazzo, C Poncet, C Thieblemont, B Coiffier, J P Magaud and G Salles
Leukemia 19: 1818-1823; advance online publication, August 11, 2005; doi:10.1038/sj.leu.2403909
Clinical and biological relevance of single-nucleotide polymorphisms and acquired somatic mutations of the BCL6 first intron in follicular lymphoma
F Jardin, P Ruminy, F Parmentier, J M Picquenot, M N Courel, P Bertrand, G Buchonnet, H Tilly and C Bastard
Leukemia 19: 1824-1830; advance online publication, August 11, 2005; doi:10.1038/sj.leu.2403915
Myeloma
Fludarabine plus cyclophosphamide in Waldenström's macroglobulinemia: results in 49 patients
J Tamburini, V Lévy, C Chaleteix, J P Fermand, A Delmer, L Stalniewicz, P Morel, F Dreyfus, M J Grange, B Christian, S Choquet and V Leblond
Leukemia 19: 1831-1834; advance online publication, August 25, 2005; doi:10.1038/sj.leu.2403885
Spotlight Correspondence
Combination of imatinib with rapamycin or RAD001 acts synergistically only in Bcr-Abl-positive cells with moderate resistance to imatinib
J Dengler, N von Bubnoff, T Decker, C Peschel and J Duyster
Leukemia 19: 1835-1838; advance online publication, June 30, 2005; doi:10.1038/sj.leu.2403848
Correspondence
ALK-positive diffuse large B-cell lymphoma with ALK-Clathrin fusion belongs to the spectrum of pediatric lymphomas
S Gesk, R D Gascoyne, B Schnitzer, N Bakshi, D Janssen, W Klapper, J I Martín-Subero, R Parwaresch and R Siebert
Leukemia 19: 1839-1840; advance online publication, August 18, 2005; doi:10.1038/sj.leu.2403921
Fulminant B hepatitis in a surface antigen-negative patient with B-cell chronic lymphocytic leukaemia after rituximab therapy
P Niscola, M I Del Principe, L Maurillo, A Venditti, F Buccisano, D Piccioni, S Amadori and G Del Poeta
Leukemia 19: 1840-1841; advance online publication, August 11, 2005; doi:10.1038/sj.leu.2403914
Mutations of the Notch1 gene in T-cell acute lymphoblastic leukemia: analysis in adults and children
S-Y Lee, K Kumano, S Masuda, A Hangaishi, J Takita, K Nakazaki, M Kurokawa, Y Hayashi, S Ogawa and S Chiba
Leukemia 19: 1841-1843; advance online publication, August 4, 2005; doi:10.1038/sj.leu.2403896
JAK2 Val617Phe activating tyrosine kinase mutation in juvenile myelomonocytic leukemia
C Tono, G Xu, T Toki, Y Takahashi, S Sasaki, K Terui and E Ito
Leukemia 19: 1843-1844; advance online publication, August 4, 2005; doi:10.1038/sj.leu.2403903
Immunophenotypic modulation in childhood precursor-B-ALL can be mimicked in vitro and is related to the induction of cell death
A J van der Sluijs-Gelling, V H J van der Velden, E T J M Roeffen, A J P Veerman and E R van Wering
Leukemia 19: 1845-1847; advance online publication, August 18, 2005; doi:10.1038/sj.leu.2403911
Clinical implications of the JAK2 V617F mutation in essential thrombocythemia
E Antonioli, P Guglielmelli, A Pancrazzi, C Bogani, M Verrucci, V Ponziani, G Longo, A Bosi and A M Vannucchi
Leukemia 19: 1847-1849; advance online publication, August 4, 2005; doi:10.1038/sj.leu.2403902
NK cell subsets and CD107a mobilization assay
J Zimmer, E Andrès and F Hentges
Leukemia 19: 1849-1851; advance online publication, August 4, 2005; doi:10.1038/sj.leu.2403906
Chronic myeloid leukemia CD34+ cells have elevated levels of phosphatidylinositol 3,4,5 trisphosphate (PtdIns(3,4,5)P3) and lack a PtdIns(3,4,5)P3 response to cytokines and chemotactic factors; effects reversed by imatinib
H G Hamzah, A Pierce, W A Stewart, C Peter Downes, A Gray, A Irvine, E Spooncer and A D Whetton
Leukemia 19: 1851-1853; advance online publication, August 18, 2005; doi:10.1038/sj.leu.2403919
Epigenetic mechanisms do not control viral latency III in primary effusion lymphoma cells infected with a recombinant Epstein–Barr virus
E Anastasiadou, F Boccellato, M Cirone, L L Kis, E Klein, L Frati, A Faggioni and P Trivedi
Leukemia 19: 1854-1856; advance online publication, August 4, 2005; doi:10.1038/sj.leu.2403895
Reply to 'NK cell subsets and CD107a mobilization assay' by Zimmer et al
O Penack, C Gentilini, L Fischer, A M Asemissen, C Scheibenbogen, E Thiel and L Uharek
Leukemia 19: 1857; advance online publication, August 11, 2005; doi:10.1038/sj.leu.2403908
